<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported):
July 17, 2000
AVANT IMMUNOTHERAPEUTICS, INC.
(Exact Name of Registrant as specified in its charter)
<TABLE>
<S> <C> <C>
Delaware 0-15006 13-3191702
(State or other jurisdiction (Commission File (I.R.S. Employer
of incorporation) Number) Identification No.)
</TABLE>
119 Fourth Avenue, Needham, MA 02494
(Address of principal executive offices and zip code)
(781) 433-0771
(Registrant's telephone number, including area code)
<PAGE>
ITEM 5. OTHER EVENTS
On July 17, 2000, Avant Immunotherapeutics, Inc. (the "Company") issued
the press release (attached as Exhibit 99.1 to this Current Report on Form 8-K)
announcing the private offering of unregistered securities of the Company.
Pursuant to a registration rights agreement entered into in connection
with the private offering, the Company has agreed to file a registration
statement registering the stock purchased in the offering within twenty days of
the closing of the offering.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits
EXHIBIT NO. DESCRIPTION
99.1 Press release announcing the private offering of
unregistered securities of the Company.
2
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
<TABLE>
<S> <C>
Dated: July 19, 2000 AVANT IMMUNOTHERAPEUTICS, INC.
By: /s/ Una S. Ryan, PhD.
-------------------------
Una S. Ryan, Ph.D.
President, Chief Executive Officer and
Assistant Secretary
</TABLE>
3
